Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


Summary - Prof. Peters // ASCOSCOPY / ASCO DIRECT

In this presentation, Professor Peters from the University Hospital Lausanne presents a short summary of the ASCO2020 virtual Meeting.

  • Sponsors

    This program is editorially independent and is financially supported by:

Related items

Congress news 22/06/2020

ASCO Discussion Round II: Highlights from a European Perspective

In this second round table discussion, experts from Switzerland and Germany discuss practice-changing studies in the fields of Head & Neck Tumors and Lung Cancer with the ASCO2020 original authors.  The following authors are presenting their studies:  Prof. Dr. Kevin Joseph Harrington The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).            Prof. Dr. Martin Reck LungenClinic Grosshansdorf, Grosshansdorf, Germany Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.   Prof. Dr. Joel Guigay                 Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, France TPExtreme randomized trial: Quality of Life (QoL) and survival according to second-line treatments in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).   John Kuruvilla, MD (Dr.) Princess Margaret Cancer Centre, Toronto, ON, Canada KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round III: Highlights from a European Perspective

In this third live discussion round, experts from Switzerland and Germany discuss practice-changing studies in the fields of GU, Immunoncology and Hematology with the ASCO2020 original authors.  The following authors are presenting their studies:  Dr. Thierry André Sorbonne University and Saint-Antoine Hospital, Paris, France Pembrolizumab Versus Chemotherapy for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: The Phase 3 KEYNOTE-177 Study   Prof. Dr. Shaji Kumar Mayo Clinic, Rochester, MN, USA Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.   Dr. Landon Carter Brown Duke Cancer Institute, Durham, North Carolina, USA Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.   Dr. Jesus G. Berdeja Sarah Cannon Research Institute, Nashville, TN, USA Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.   Prof. Dr. Thomas Powles Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, London, UK Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.

Congress news 22/06/2020

ASCO Discussion Round I: Highlights from a European Perspective

In this discussion, round experts from Switzerland and Germany discuss practice-changing studies with the ASCO2020 original authors.  The following authors are presenting their studies:    Dr. Fatima Cardoso         Breast Cancer Unit, Champalimaud Cancer Center, Lisbon, Portugal MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients   Dr. Javier Cortes Breast Cancer Program, IOB Institute of Oncology, Madrid & Barcelona, Spain                      KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.   Prof. Dr. Andreas du Bois Department Gynecology & Gyn.Oncology KEM, Evang. Kliniken Essen-Mitte gGmbH, Essen, Germany Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20.   ASCO DirectTM is a multi-sponsoring project and one of the American Society of Clinical Oncology® (ASCO®) licensed services.